Evidence map›Paper›PMID 32340083›Full record

ArticleCancer research and treatment2020

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.

Ying Lin, Mingxi Lin, Jian Zhang, Biyun Wang, Zhonghua Tao, Yiqun Du, Sheng Zhang, Jun Cao, Leiping Wang, Xichun Hu

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04646759 (Fulvestrant or Capecitabine Combined With Pyrotinib in HR-positive and HER2-Positive Metastatic Breast Cancer), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04646759 phase3recruitingnot on this map

Fulvestrant or Capecitabine Combined With Pyrotinib in HR-positive and HER2-Positive Metastatic Breast Cancer: A Multicenter, Randomized, Phase III Study

TypeinterventionalSponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRan2020 to 2030Enrolled516ConditionsBreast CancerArmsFulvestrant combined with Pyrotinib, Capecitabine combined with Pyrotinib
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2023
    Article
  19. Review
  20. Efficacy and safety of pyrotinib and radiotherapyAnnals of translational medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ying LinDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Mingxi LinDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jian ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Biyun WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhonghua TaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yiqun DuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Sheng ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jun CaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Leiping WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CN

Funding

Shanghai Anticancer Association SACACY1B03Shanghai Hospital Development Center SHDC12018X03Shanghai Municipal Commission of Health and Family Planning 201640069Shanghai Municipal Science and Technology Commission 18411967800Shanghai Natural Science Foundation 17ZR1405700
6 · The paper itself

Abstract

purposePyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), focusing on efficacy in lapatinib-treated patients and in brain metastasis. MATERIALS AND

methodsOne hundred thirteen patients with metastatic HER2-positive BC treated with pyrotinib-based therapy in Fudan University Shanghai Cancer Center under non-clinical trial settings from September 1, 2018 to March 1, 2019 were included.

resultsOver half patients have received more than two lines of systematic therapy and exposed to two or more kinds of anti-HER2 agents. Most patients received a combined therapy, commonly of pyrotinib plus capecitabine, or vinorelbine or trastuzumab. Median progression-free survival (PFS) was 6.3 months (range, 5.54 to 7.06 months) and objective response rate (ORR) was 29.5%, with two patients (1.9%) achieving complete response. Lapatinib-naïve patients had significantly longer PFS than lapatinib-treated patients (9.0 months vs. 5.4 months, p=0.001). ORR for lapatinib-treated patients was 23.2%. Thirty-one of 113 patients have brain metastasis. Median PFS was 6.7 months and intracranial ORR was 28%. For patients without concurrent radiotherapy and/or brain surgery, the ORR was very low (6.3%). But for patients receiving concurrent radiotherapy and/or brain surgery, the ORR was 66.7%, and three patients achieved complete response. Most common adverse event was diarrhea.

conclusionPyrotinib-based therapy demonstrated promising effects in metastatic HER2-positive BC and showed activity in lapatinib-treated patients. For patients with brain metastasis, pyrotinib-based regimen without radiotherapy showed limited efficacy, but when combined with radiotherapy it showed promising intracranial control.

Indexed as

AcrylamidesAdultAgedAged, 80 and overAminoquinolinesAntineoplastic Combined Chemotherapy ProtocolsBiopsyBrainBrain NeoplasmsBreastBreast NeoplasmsCapecitabineChemoradiotherapy, AdjuvantChinaDisease-Free SurvivalDrug Resistance, NeoplasmAcrylamidesAminoquinolinesCapecitabineERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLapatinibpyrotinibTrastuzumabVinorelbineBrain metastasisHER2-positive breast cancerLapatinib-treatedPyrotinibTyrosine kinase inhibitor

Identifiers

PMID32340083
PMCPMC7577809
OpenAlexW3020082109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.